6600.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (20 6月 2024 @ 17:08):
Our systems believe the stock currently is overvalued by -0.01% compare to its pairs and should correct downwards.

Stats
本日の出来高	33.64M
平均出来高	4.73M
時価総額	11.80B
EPS	HKD0.380 ( Q4 \| 2023-12-31 )
Last Dividend	HKD0.390 ( 2023-06-02 )
Next Dividend	HKD0 ( N/A )
P/E	10.12 (Sector) 0 (Industry) 6.31
ATR14	HKD0.0120 (0.06%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

相関 (AI algo v.1.1b): Overvalued: -0.01% HKD18.72 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: -0.01 (neutral)

短: -0.46 (neutral)

Signal:(60.886) Neutral

SciClone Pharmaceuticals, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

SciClone Pharmaceuticals, 相関 - 通貨/商品

-0.05
( neutral )

0.03
( neutral )

0.00
( neutral )

0.02
( neutral )

SciClone Pharmaceuticals, 財務諸表

Annual	2023
収益:	HKD3.16B
総利益:	HKD2.36B (74.67 %)
EPS:	HKD1.830

FY	2023
収益:	HKD3.16B
総利益:	HKD2.36B (74.67 %)
EPS:	HKD1.830

FY	2022
収益:	HKD2.75B
総利益:	HKD2.07B (75.30 %)
EPS:	HKD1.270

FY	2021
収益:	HKD2.52B
総利益:	HKD1.93B (76.75 %)
EPS:	HKD1.420

Financial Reports:

No articles found.

SciClone Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.390 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

SciClone Pharmaceuticals, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.05 - Potential for dividend initiation, but uncertain (20.92%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.350	2022-05-27
Last Dividend	HKD0.390	2023-06-02
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	HKD0.740	--
Avg. Dividend % Per Year	0.00%	--
Score	3.21	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.05
Div. Directional Score	8.97	--

Next Divdend (Est)
(2025-03-31)

HKD0.327 Estimate 3.00 %

Dividend Stability

0.24 Very Poor

Dividend Score

3.21

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
02 Jun 2023	HKD0.390	30 Nov -0001	30 Nov -0001	30 Nov -0001
27 May 2022	HKD0.350	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
1888.HK	Ex Dividend Knight	2023-12-12	Semi-Annually	0.00%
0303.HK	Ex Dividend Knight	2023-07-21	Semi-Annually	0.00%
1358.HK	Ex Dividend Junior	2023-09-29	Annually	0.00%
0010.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
3759.HK	Ex Dividend Knight	2023-07-18	Annually	0.00%
0922.HK	Ex Dividend Junior	2023-09-13	Sporadic	0.00%
2148.HK	Ex Dividend Knight	2023-10-03	Sporadic	0.00%
0522.HK	Ex Dividend Junior	2023-08-14	Semi-Annually	0.00%
1658.HK	Ex Dividend Junior	2023-07-05	Annually	0.00%
0105.HK	Ex Dividend Knight	2023-09-19	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.356	1.500	2.89	4.33	[0 - 0.5]
returnOnAssetsTTM	0.280	1.200	0.651	0.782	[0 - 0.3]
returnOnEquityTTM	0.369	1.500	7.01	10.00	[0.1 - 1]
payoutRatioTTM	0.192	-1.000	8.08	-8.08	[0 - 1]
currentRatioTTM	4.94	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.43	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.59	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00821	-1.500	9.86	-10.00	[0 - 0.6]
interestCoverageTTM	40.04	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.16	2.00	8.92	10.00	[0 - 20]
debtEquityRatioTTM	0.0101	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.747	1.000	0.889	0.889	[0.2 - 0.8]
operatingProfitMarginTTM	0.430	1.000	3.40	3.40	[0.1 - 0.6]
cashFlowToDebtRatioTTM	42.77	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.789	0.800	8.07	6.46	[0.5 - 2]
Total Score				11.89

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.08	1.000	9.08	0	[1 - 100]
returnOnEquityTTM	0.369	2.50	8.08	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
payoutRatioTTM	0.192	1.500	8.08	-8.08	[0 - 1]
pegRatioTTM	0.641	1.500	9.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.445	1.000	1.375	0	[0.1 - 0.5]
Total Score				6.05

SciClone Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

SciClone Pharmaceuticals,

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.